We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

30 hedge funds and large institutions have $13.4M invested in Xilio Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

48% more capital invested

Capital invested by funds: $9.1M → $13.4M (+$4.34M)

1.06% less ownership

Funds ownership: 4.29% → 3.23% (-1.1%)

9% less funds holding

Funds holding: 33 → 30 (-3)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
30
Holders Change
-3
Holders Change %
-9.09%
% of All Funds
0.43%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
6
Increased
3
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$233K
2
Millennium Management
Millennium Management
New York
+$27.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$27.4K
4
SFG
SevenBridge Financial Group
Pennsylvania
+$21.4K
5
PI
PFG Investments
New York
+$20.7K

Top Sellers

1
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$1.22M
2
OCA
Octagon Capital Advisors
New York
-$982K
3
AG
Artal Group
Luxembourg
-$248K
4
LCM
Laurion Capital Management
New York
-$64.3K
5
BCM
Bridgeway Capital Management
Texas
-$58.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$3.03M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$2.06M – – –
TPC
3
Takeda Pharmaceutical Company
Japan
$1.59M – – –
RVM
4
RiverVest Venture Management
Missouri
$1.56M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$1.56M – – –
AVLSA
6
Atlas Venture Life Science Advisors
Massachusetts
$1.07M -$1.22M -126,174 -64%
Vanguard Group
7
Vanguard Group
Pennsylvania
$975K – – –
Balyasny Asset Management
8
Balyasny Asset Management
Illinois
$366K +$233K +24,182 New
Renaissance Technologies
9
Renaissance Technologies
New York
$269K +$27.4K +2,839 +19%
Morgan Stanley
10
Morgan Stanley
New York
$240K -$22.5K -2,331 -13%
Fidelity International
11
Fidelity International
Bermuda
$236K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$91.7K – – –
BCM
13
Bridgeway Capital Management
Texas
$76.8K -$58.2K -6,029 -54%
Millennium Management
14
Millennium Management
New York
$75.8K +$27.5K +2,846 +131%
BlackRock
15
BlackRock
New York
$49K -$1.03K -107 -3%
SFG
16
SevenBridge Financial Group
Pennsylvania
$36.6K +$21.4K +2,214 New
PI
17
PFG Investments
New York
$32.4K +$20.7K +2,143 New
PCM
18
Prelude Capital Management
New York
$31.9K +$20.3K +2,107 New
Northern Trust
19
Northern Trust
Illinois
$19.2K – – –
STA
20
Summit Trail Advisors
New York
$17.3K +$11K +1,143 New
State Street
21
State Street
Massachusetts
$16.9K – – –
DF
22
Dunhill Financial
United Kingdom
$15.7K – – –
Charles Schwab
23
Charles Schwab
California
$12.9K – – –
TRCT
24
Tower Research Capital (TRC)
New York
$12K -$1.94K -201 -20%
JP Morgan Chase
25
JP Morgan Chase
New York
$2.96K -$77 -8 -4%
1
2

XLO Hedge Fund Activity: Q1 2024 in Review

30 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2024, worth a combined $13.4M — up 48% from $9.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of XLO and 6 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 3 added.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $233K. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $1.22M.

  • 30 institutional investors held Xilio Therapeutics (XLO) as of Q1 2024, down from 33 in Q4 2023.
  • Funds reported $13.4M of Xilio Therapeutics stock for Q1 2024, up 48% quarter-over-quarter.
  • 6 funds opened new Xilio Therapeutics positions in Q1 2024 and 8 closed out, a net change of -2 holders.
  • The largest Xilio Therapeutics buyer in Q1 2024 was Balyasny Asset Management, an estimated $233K added.
  • The largest Xilio Therapeutics seller in Q1 2024 was Atlas Venture Life Science Advisors, an estimated $1.22M sold.

Based on aggregated 13F filings for Q1 2024.